|Day Low/High||67.92 / 69.17|
|52 Wk Low/High||60.89 / 85.97|
Microsoft says it will miss its personal computer forecast, but Marriott appears to be trading up a tad.
Hot money will be attracted to stocks that show promise in dealing with the coronavirus.
Only one of these scenarios is going to get you in and out of this market with your assets intact and your portfolio stronger.
Is this the end of the world? No. You still need to plan for your financial well-being, even as the CDC tells us 'this might be bad.'
This entirely logical scenario would pull the rug out from under the bull market.
The answer to that question depends on several factors, so let's break them down.
I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good.
I would consider any entry a trade, and not an investment.
Any modest intraday dip is probably a buying opportunity.
Here's what the charts say about entering Gilead Sciences.
Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.
Gilead offers a nearly 4% yield and looks ready to return to growth.
RBC analysts expect Alibaba and Salesforce to continue posting strong double-digit sales growth, and remain fans of Constellation's M&A-driven growth strategy.
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
"Politics: "Poli" a Latin word meaning "many" and "tics" meaning "bloodsucking creatures" - Robin Williams Markets are looking good a half hour into the trading day. All the major indices are nicely in the black with the NASDAQ up approximately one ...
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Let's see if either of these names provide an entry this week.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.